title: Chemoinfusion of the hepatic artery for metastases to the liver.
abstract: During a five year period, 69 patients were treated for carcinoma of the liver (seven primary tumors and 62 metastatic tumors) with 5-fluorodeoxyuridine (5-FUDR) administered through a hepatic artery (n = 62) or portal vein (n = 3) implantable infusion pump. Ten patients proved to have previously unsuspected extrahepatic nodal metastases at laparotomy for pump insertion. 5-FUDR was given in 14 day cycles for three months. At the end of that period and at three month intervals thereafter (mean follow-up time of 18 months, a range of one to 60 months), patients were evaluated with roentgenograms of the chest, liver function tests, carcinoembryonic antigen levels, radionuclide scans and computed tomography. Thirty-five patients had a partial response, nine had stabilization of the disease and 25 had progression of the disease (five during therapy, who were given mitomycin C). Median regression was 6.8 months (a range of three to 18 months). Six of the 35 partial responders, three of the nine patients with stabilization and ten of the 25 patients with progression had extrahepatic visceral disease. Survival time averaged 18.4 months (a range of five to 60 months) for the partial responders, 12.6 months (a range of two to 40 months) for patients with stabilization and seven months (a range of one to 17 months) for those with progression of the disease.
authors.affiliation: Department of Surgery, Bowman Gray School of Medicine, Wake Forest University Medical Center, Winston-Salem, North Carolina 27103.
authors.forename: J M
authors.initials: JM
authors.lastname: Sterchi
authors.forename: F
authors.initials: F
authors.lastname: Richards
authors.forename: D R
authors.initials: DR
authors.lastname: White
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: M R
authors.initials: MR
authors.lastname: Cooper
authors.forename: D V
authors.initials: DV
authors.lastname: Jackson
authors.forename: C L
authors.initials: CL
authors.lastname: Spurr
authors.forename: R L
authors.initials: RL
authors.lastname: Capizzi
authors.forename: J
authors.initials: J
authors.lastname: Cruz
authors.forename: P J
authors.initials: PJ
authors.lastname: Zekan
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006499:Hepatic Artery; D006801:Humans; D007260:Infusion Pumps; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed
chemical_list: D005467:Floxuridine